http://orcid.org/0000-0001-8662-3599
About the Authors
- Ronald B. Moss
-
Roles Conceptualization
* E-mail: rmoss@adamispharma.com
Affiliation Adamis Pharmaceuticals Corp, San Diego, CA, United States of America
- Meghan McCabe Pryor
-
Roles Data curation
Affiliation Rosa & Co. LLC, San Carlos, CA, United States of America
- Rebecca Baillie
-
Roles Formal analysis
Affiliation Rosa & Co. LLC, San Carlos, CA, United States of America
- Katherine Kudrycki
-
Roles Formal analysis
Affiliation Rosa & Co. LLC, San Carlos, CA, United States of America
- Christina Friedrich
-
Roles Formal analysis
Affiliation Rosa & Co. LLC, San Carlos, CA, United States of America
- Mike Reed
-
Roles Formal analysis
Affiliation Rosa & Co. LLC, San Carlos, CA, United States of America
- Dennis J. Carlo
-
Roles Formal analysis
Affiliation Adamis Pharmaceuticals Corp, San Diego, CA, United States of America
Competing Interests
The authors have read the journal's policy and the authors of this paper have the following competing interests: RBM and DJC are paid employees of Adamis Pharmaceuticals and have equity in the company. MMP, RB, KK, CF, and MR are paid employees of Rosa & Co and have equity in the company. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Adamis Pharmaceuticals is developing a high dose naloxone product for the treatment of opioid overdose.